Hepatocellular carcinoma (HCC) remains a formidable clinical challenge due to its aggressive nature and resistance to conventional therapies. Sorafenib, a multi-kinase inhibitor, has been the standard systemic therapy for advanced HCC; however, its efficacy is often limited by adaptive resistance mechanisms within tumor cells. The metabolic flexibility of cancer cells, allowing them to survive under hostile microenvironments, has been increasingly recognized as a key contributor to therapeutic failure. The current report emphasizes that targeting circadian regulators governing metabolic pathways may disrupt these adaptive circuits and restore drug sensitivity.

REV-ERBs, nuclear receptors implicated in circadian rhythm regulation, also exert profound control over cellular metabolism, including glucose and lipid homeostasis. SR9009 is a synthetic agonist of REV-ERB, designed to modulate these metabolic pathways by engaging REV-ERBα and REV-ERBβ isoforms. Previous studies have hinted at SR9009’s capacity to disrupt cancer cell metabolism, but its synergistic potential with existing chemotherapeutics remained unclear until now. The new research delineates a molecular framework whereby SR9009 interferes with mitochondrial biogenesis and oxidative phosphorylation, effectively eroding the energy reserves of hepatocarcinoma cells.

At the mechanistic level, the combination of SR9009 with sorafenib was shown to induce pronounced inhibition of key signaling pathways involved in tumor survival and proliferation. Notably, the dual treatment suppressed the PI3K/AKT/mTOR axis, a central node frequently upregulated in liver cancer and associated with chemoresistance. This suppression translated into enhanced apoptosis and diminished cellular viability in vitro, as well as significant tumor regression in murine xenograft models. These results suggest that SR9009 primes tumor cells to become more susceptible to sorafenib-induced cytotoxicity by rewiring metabolic and signaling networks.

Cellular bioenergetics studies revealed that SR9009 triggers a state of metabolic crisis within HCC cells by downregulating enzymes critical for glycolysis and mitochondrial respiration. This energy depletion stresses the cancer cells, impairing their proliferative capacity and making them more vulnerable to sorafenib’s inhibitory effects on angiogenesis and cell cycle progression. The authors highlight that the timing of administration may be crucial since REV-ERB function oscillates with circadian rhythms, underscoring the importance of chronotherapy principles in maximizing drug synergy.

Importantly, the study was complemented by transcriptomic analyses which showcased global shifts in gene expression profiles upon SR9009 treatment. Genes involved in lipid metabolism, reactive oxygen species detoxification, and cell stress responses were markedly modulated. These transcriptional changes not only disrupt metabolic balance but also sensitize tumor cells to oxidative damage induced by sorafenib. The dual assault on metabolism and survival pathways represents a two-pronged strategy that could overcome the adaptive resistance mechanisms that limit current liver cancer treatments.

The translational potential of this work cannot be overstated. Liver cancer patients often face limited options beyond sorafenib, with few advances in last-decade systemic therapies. Incorporating REV-ERB agonists like SR9009 into therapeutic regimens could revitalize the utility of sorafenib, enhancing response rates and potentially extending patient survival. Moreover, as SR9009 targets fundamental metabolic processes, this strategy may also show efficacy across heterogeneous tumor populations who vary in molecular subtype and drug responsiveness.

While preclinical data are robust, clinical trials assessing safety, dosing, and efficacy of the SR9009 and sorafenib combination will be needed to fully realize this strategy’s promise. The study’s authors call for urgent advancement into early phase patient studies, suggesting biomarker-guided approaches to select patients most likely to benefit from this metabolic sensitization. Integration of metabolic imaging and circadian profiling could further refine treatment scheduling and response monitoring in clinical settings.

Beyond liver cancer, this research opens broader avenues for targeting the circadian-metabolic interface in oncology. The clock-metabolism axis is increasingly recognized as a universal vulnerability in diverse malignancies, where metabolic reprogramming fuels growth and resistance. REV-ERB agonists could emerge as a novel class of metabolic therapies to be combined with cytotoxic drugs, immunotherapies, or targeted agents, fundamentally altering the landscape of cancer therapeutics.

The mechanistic insights gained from this study also enrich our understanding of tumor biology, highlighting the interplay between circadian regulators and oncogenic signaling cascades. Such knowledge could enable the design of precision medicine approaches that not only target genetic drivers but also the dynamic metabolic states of tumors, thus improving therapeutic windows and minimizing off-target effects.

Challenging the dogma of fixed dosing, the demonstrated importance of the circadian rhythm in drug sensitivity advocates for chronotherapeutic interventions. Optimizing drug administration according to endogenous molecular clocks may enhance efficacy and reduce toxicities, a principle underscored by the strategic use of REV-ERB agonists in timing therapy. This temporal dimension of cancer treatment represents the frontier of personalized medicine.

The integration of SR9009’s effects on mitochondrial dynamics underscores a critical vulnerability of cancer cells reliant on high metabolic output. By attenuating mitochondrial function, the study exposes a biochemical bottleneck that can be leveraged alongside kinase inhibition. This dual disruption potentiates cellular stress beyond compensatory limits, guiding tumor cells toward apoptosis and growth arrest.

Furthermore, the research highlights the role of metabolic checkpoint pathways as gatekeepers of drug resistance, suggesting new targets for pharmacological intervention. By converging on these checkpoints, the combined therapy not only impairs tumor growth but may also prevent or delay the emergence of resistant clones, a major obstacle in current cancer treatment paradigms.

In sum, the discovery that the REV-ERB agonist SR9009 can synergistically enhance sorafenib efficacy heralds a new era in liver cancer therapy—one that harnesses the power of metabolic reprogramming and circadian biology to outmaneuver resilient tumors. This innovative approach offers a beacon of hope to patients and clinicians alike, promising more effective, tailored, and sustainable cancer care.

As the oncology field pursues this promising therapeutic avenue, it is incumbent upon the scientific community to accelerate translational efforts, embrace chronobiology insights, and refine metabolic interventions. Collectively, these advances signal a transformative leap toward conquering liver cancer by exploiting its own metabolic Achilles’ heel.

Subject of Research:

Liver cancer therapy enhancement through metabolic targeting using REV-ERB agonist SR9009 combined with sorafenib.

Article Title:

Targeting metabolic vulnerabilities: REV-ERB agonist SR9009 potentiates sorafenib efficacy in liver cancer.

Article References:

Sabbioni, S., Guerriero, P., Shankaraiah, R.C. et al. Targeting metabolic vulnerabilities: REV-ERB agonist SR9009 potentiates sorafenib efficacy in liver cancer.
Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-02940-3

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-02940-3

Understanding the metabolic vulnerabilities of cancer cells has long been a cornerstone of cancer biology. A critical metabolite in this landscape is acetyl-coenzyme A (acetyl-CoA), a pivotal molecule involved in energy metabolism, lipid synthesis, and epigenetic modulation. Elevated levels of acetyl-CoA have been documented to drive cancer metastasis, yet the precise source of this metabolite within the tumor microenvironment remained elusive. The innovative work spearheaded by Shen and colleagues uncovers that TAMs secrete acetate, a key precursor metabolite, which tumor cells avidly take up to maintain high intracellular acetyl-CoA levels critical for metastatic behavior.

This discovery uncovers a previously unappreciated metabolic symbiosis: HCC tumor cells secrete lactate into their surrounding environment, which paradoxically activates a metabolic pathway in TAMs characterized by lipid peroxidation and the enzymatic activity of aldehyde dehydrogenase 2 (ALDH2). This activation triggers TAMs to convert lipid peroxidation products into acetate, which they then release back into the microenvironment. In essence, HCC cells manipulate TAMs to produce a vital fuel—acetate—creating a reciprocal loop that supports tumor aggressiveness.

Delving deeper into the molecular mechanisms, the study highlights ALDH2 as a linchpin enzyme driving the acetate-producing capability of TAMs. Lipid peroxidation generates reactive aldehydes that can be detoxified and metabolized into acetate by ALDH2. By pharmacologically inhibiting ALDH2 or blocking lipid peroxidation processes within TAMs, the researchers effectively curtailed acetate production. Remarkably, this intervention suppressed the migratory and invasive capabilities of HCC cells in vitro, underscoring the potential therapeutic value of targeting this metabolic axis to restrain cancer dissemination.

The researchers then translated these in vitro findings into an orthotopic HCC mouse model, employing genetic ablation to selectively eliminate ALDH2 within TAMs. This genetic intervention yielded profound reductions in acetate availability within tumor cells and correspondingly led to a marked decrease in lung metastases. These in vivo results validate the pivotal role of TAM-derived acetate in facilitating metastatic spread and potentiate ALDH2 inhibition as a promising anti-metastatic strategy.

This study elegantly bridges the gap between metabolic biochemistry and tumor immunology by portraying TAMs not merely as passive bystanders or immune effectors but as active metabolic accomplices that nurture cancer progression. The metabolic plasticity of TAMs, particularly their ability to harness lipid peroxidation pathways to generate acetate, reveals a layer of complexity in tumor-stroma interactions that had previously gone unappreciated.

The implications of these findings extend beyond HCC, potentially informing understanding in other malignancies where macrophage infiltration and acetate metabolism intersect. Tumors are known to exploit local microenvironmental factors, including immune cells and metabolic substrates, to thrive and metastasize. Un covering the metabolic dialogue that enables such exploitation offers innovative angles for therapeutic intervention, particularly in combating metastasis, the primary cause of cancer mortality.

It is also significant that the study positions lactate, a common metabolic byproduct of cancer cells’ glycolytic metabolism, as a key mediator orchestrating acetate production in TAMs. This recasts lactate from a mere waste product to a signaling molecule within the tumor milieu, modulating immune cell metabolism to favor cancer progression. Such insights contribute to a growing appreciation of lactate’s dual role as a metabolic substrate and an immunomodulatory signal in cancer.

Targeting ALDH2 enzymatic activity emerges as a compelling therapeutic route. Given ALDH2’s role in detoxifying lipid peroxidation aldehydes and facilitating acetate production, inhibiting this enzyme may cripple the metabolic support TAMs provide to tumor cells. This therapeutic approach could synergize with existing treatments, potentially mitigating metastatic dissemination and improving patient outcomes.

Moreover, these findings prompt a re-evaluation of how tumor microenvironments are conceptualized—highlighting the dynamic metabolic interdependencies between cancer cells and surrounding stromal and immune elements. Recognizing that immune cells such as TAMs can serve as reservoirs and factories for critical metabolites may revolutionize strategies to disrupt tumor metabolism at multiple fronts.

The complexity of lipid peroxidation pathways in TAMs, implicated in this acetate production, also invites further investigation. Understanding the specific lipid substrates undergoing peroxidation, and the signals triggering this process in TAMs when exposed to tumor-derived lactate, could reveal additional molecular targets to disrupt this metabolic crosstalk.

In light of these insights, future research may explore how modulation of microenvironmental acetate levels impacts epigenetic modifications in cancer cells, given acetyl-CoA’s pivotal role as a substrate for histone acetylation. This could open avenues linking metabolic regulation by TAMs to the epigenetic reprogramming that underlies metastatic competence.

Equally, the study underscores the need to consider cellular heterogeneity within the tumor microenvironment. TAM subpopulations with varying metabolic profiles might differentially contribute to acetate production and tumor support, suggesting tailored interventions might be required for maximal therapeutic efficacy.

In conclusion, the discovery that tumor-associated macrophages act as an acetate reservoir to drive hepatocellular carcinoma metastasis unveils a sophisticated metabolic alliance that enables aggressive cancer behavior. By dissecting the lactate-induced activation of lipid peroxidation and ALDH2 pathways in TAMs, this research provides a mechanistic understanding that not only advances fundamental cancer biology but also signals new frontiers for therapeutic innovation targeting the metabolic ecosystems supporting metastasis.

Subject of Research: Tumor-associated macrophages as metabolic contributors to hepatocellular carcinoma metastasis through acetate production.

Article Title: Tumour-associated macrophages serve as an acetate reservoir to drive hepatocellular carcinoma metastasis.

Article References:
Shen, L., Wang, S., Gao, C. et al. Tumour-associated macrophages serve as an acetate reservoir to drive hepatocellular carcinoma metastasis. Nat Metab (2025). https://doi.org/10.1038/s42255-025-01393-9

Image Credits: AI Generated